LIQUID BIOPSY IN GYNECOLOGIC ONCOLOGY: CURRENT STATUS AND FUTURE PERSPECTIVES

Liquid biopsy has rapidly evolved from a research concept into a clinically relevant approach for capturing tumor-derived information through minimally invasive sampling, most commonly from blood but increasingly from other fluids that are highly relevant to gynecologic malignancies. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells, extracellular vesicles, and circulating RNA species, liquid biopsy can complement tissue pathology by offering real-time molecular insights, enabling longitudinal monitoring, and potentially detecting relapse earlier than conventional methods.